within Pharmacolibrary.Drugs.ATC.L;

model L01EC01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.49,
    Cl             = 0.5316666666666666,
    adminDuration  = 600,
    adminMass      = 0.96,
    adminCount     = 1,
    Vd             = 0.106,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0015,
    Tlag           = 156.0
  );

  annotation(Documentation(
    info ="<html><body><p>Vemurafenib is an oral small molecule inhibitor of the BRAF serine-threonine kinase, specifically targeting the BRAF V600E mutation. It is primarily approved for the treatment of unresectable or metastatic melanoma with BRAF V600E mutation and is currently used clinically for this indication.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetic analysis in adult cancer patients (melanoma), both sexes, oral dosing at steady state.</p><h4>References</h4><ol><li>Weijiang Zhang, Dominik Heinzmann, Joseph F Grippo,Clinical Pharmacokinetics of Vemurafenib.,Clinical pharmacokinetics,2017<a href='https://pubmed.ncbi.nlm.nih.gov/28255850/'>https://pubmed.ncbi.nlm.nih.gov/28255850/</a></li><li>Hechuan Wang, Janel Long-Boyle, Beth Apsel Winger, Theodore Nicolaides, Sabine Mueller, Michael Prados, Vijay Ivaturi,Population Pharmacokinetics of Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E-Mutant Astrocytomas.,Journal of clinical pharmacology,2020<a href='https://pubmed.ncbi.nlm.nih.gov/32476174/'>https://pubmed.ncbi.nlm.nih.gov/32476174/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01EC01;
